Previous 10 | Next 10 |
STAMFORD, Conn., May 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today ann...
STAMFORD, Conn., May 07, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, toda...
STAMFORD, Conn., May 04, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced tha...
You can't lump all clinical-stage biotechs together. Take Cara Therapeutics (NASDAQ: CARA) and Sangamo Therapeutics (NASDAQ: SGMO) , for example. The two biotechs are about as different as night and day. One thing that both Cara and Sangamo have in common, though, are promising ...
As we fast approach May, it seems as though a lot of focus continues to be paid to marijuana stocks . In the past two months, we have witnessed a large amount of bearish sentiment in the cannabis market simply due to the overwhelming issues with coronavirus. The pandemic has caused a lot of iss...
Shares of clinical-stage biotech Cara Therapeutics (NASDAQ: CARA) rose 4% Tuesday after the company reported successful results from a phase 3 trial of its lead drug Korsuva for pruritis, or severe itching, in hemodialysis patients. Based on the results, Cara and its partner, Fresenius...
Energous (NASDAQ: WATT ) +143% on FCC certification . More news on: Energous Corporation, Vaxart, Inc., My Size, Inc., Stocks on the move, , Read more ...
Cara Therapeutics (NASDAQ: CARA ) and licensee Vifor Fresenius Medical Care Renal Pharma announce positive results from a Phase 3 clinical trial, KALM-2 , evaluating Korsuva (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated ...
Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo (p=0.02) - Statistically significant improvement in key secondary endpoint of proportion of patients with...
Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02) Statistically significant improvement in key secondary endpoint of proportion of patients with fo...
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...